Elanco Animal Health Incorporated APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Elanco Animal Health Incorporated (ELAN) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $20.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-05
- Elanco Animal Health Incorporated apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $20.00M, a 0.00% change year-over-year.
- Elanco Animal Health Incorporated apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was -$12.00M, a 700.00% decline year-over-year.
- Elanco Animal Health Incorporated apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $15.00M, a 7.14% increase year-over-year.
- Elanco Animal Health Incorporated apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $20.00M, a 53.85% increase year-over-year.
- Elanco Animal Health Incorporated apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $53.00M, a 32.50% increase from fiscal 2024.
- Elanco Animal Health Incorporated apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $40.00M, a 2.56% increase from fiscal 2023.
- Elanco Animal Health Incorporated apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $39.00M, a 7.14% decline from fiscal 2022.
- Elanco Animal Health Incorporated apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $42.00M, a 8.70% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $20.00M 10-Q · filed 2026-08-05 | $8.00M derived: sum of 2 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | -$12.00M 10-Q · filed 2026-08-05 | |||||
| 2025-12-31 | $53.00M 10-K · filed 2026-02-24 | |||||
| 2025-09-30 | $15.00M 10-Q · filed 2025-11-05 | $35.00M derived: sum of 2 quarters · filed 2026-08-05 | $37.00M derived: sum of 3 quarters · filed 2026-08-05 | |||
| 2025-06-30 | $20.00M 10-Q · filed 2026-08-05 | $22.00M derived: sum of 2 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $2.00M 10-Q · filed 2026-08-05 | |||||
| 2024-12-31 | $40.00M 10-K · filed 2026-02-24 | |||||
| 2024-09-30 | $14.00M 10-Q · filed 2025-11-05 | $27.00M derived: sum of 2 quarters · filed 2025-11-05 | ||||
| 2024-06-30 | $13.00M 10-Q · filed 2025-11-05 | |||||
| 2023-12-31 | $39.00M 10-K · filed 2026-02-24 | |||||
| 2023-09-30 | $11.00M 10-Q · filed 2024-11-07 | $19.00M derived: sum of 2 quarters · filed 2024-11-07 | $25.00M derived: sum of 3 quarters · filed 2024-11-07 | |||
| 2023-06-30 | $8.00M 10-Q · filed 2024-11-07 | $14.00M derived: sum of 2 quarters · filed 2024-11-07 | ||||
| 2023-03-31 | $6.00M 10-Q · filed 2024-11-07 | $11.00M 10-Q · filed 2023-05-09 | ||||
| 2022-12-31 | $42.00M 10-K · filed 2025-02-25 | $58.00M 10-K · filed 2023-03-01 | ||||
| 2022-09-30 | $12.00M 10-Q · filed 2023-11-07 | $13.00M 10-Q · filed 2022-11-08 | $25.00M derived: sum of 2 quarters · filed 2023-11-07 | $28.00M derived: sum of 3 quarters · filed 2023-11-07 | ||
| 2022-06-30 | $13.00M 10-Q · filed 2023-11-07 | $17.00M 10-Q · filed 2022-08-08 | $16.00M derived: sum of 2 quarters · filed 2023-11-07 | |||
| 2022-03-31 | $3.00M 10-Q · filed 2023-11-07 | $14.00M 10-Q · filed 2022-05-09 | ||||
| 2021-12-31 | $46.00M 10-K · filed 2024-02-26 | $66.00M 10-K · filed 2022-02-28 | ||||
| 2021-09-30 | $17.00M 10-Q · filed 2022-11-08 | $33.00M derived: sum of 2 quarters · filed 2022-11-08 | $48.00M derived: sum of 3 quarters · filed 2022-11-08 | |||
| 2021-06-30 | $16.00M 10-Q · filed 2022-11-08 | $31.00M derived: sum of 2 quarters · filed 2022-11-08 | ||||
| 2021-03-31 | $15.00M 10-Q · filed 2022-11-08 | |||||
| 2020-12-31 | $47.00M 10-K · filed 2023-03-01 | $47.70M 10-K · filed 2021-03-01 | ||||
| 2020-09-30 | $11.00M 10-Q · filed 2021-11-05 | $11.70M 10-Q · filed 2020-11-06 | $19.00M derived: sum of 2 quarters · filed 2021-11-05 | $30.00M derived: sum of 3 quarters · filed 2021-11-05 | ||
| 2020-06-30 | $8.00M 10-Q · filed 2021-11-05 | $8.30M 10-Q · filed 2020-07-30 | $19.00M derived: sum of 2 quarters · filed 2021-11-05 | |||
| 2020-03-31 | $11.00M 10-Q · filed 2021-11-05 | $11.10M 10-Q · filed 2020-05-07 | ||||
| 2019-12-31 | $41.00M 10-K · filed 2022-02-28 | $40.70M 10-K · filed 2020-02-28 | ||||
| 2019-09-30 | $11.30M 10-Q · filed 2020-11-06 | $25.60M derived: sum of 2 quarters · filed 2020-11-06 | $28.00M derived: sum of 3 quarters · filed 2020-11-06 | |||
| 2019-06-30 | $14.30M 10-Q · filed 2020-11-06 | $16.70M derived: sum of 2 quarters · filed 2020-11-06 | ||||
| 2019-03-31 | $2.40M 10-Q · filed 2020-11-06 | |||||
| 2018-12-31 | $1.80M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |